Legal & General Group Plc Acquires Shares of 41,697 Corvus Pharmaceuticals, Inc. $CRVS

Legal & General Group Plc bought a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the second quarter, Holdings Channel.com reports. The institutional investor bought 41,697 shares of the company’s stock, valued at approximately $623,000.

A number of other large investors have also made changes to their positions in CRVS. Global Retirement Partners LLC acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $30,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Corvus Pharmaceuticals during the second quarter worth $48,000. Quarry LP acquired a new position in Corvus Pharmaceuticals during the third quarter worth $27,000. State of Wyoming purchased a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at $71,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth $90,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Price Performance

Shares of CRVS stock opened at $13.93 on Wednesday. The firm has a market cap of $1.17 billion, a PE ratio of -22.84 and a beta of 0.87. The company has a 50-day moving average of $14.43 and a two-hundred day moving average of $14.43. Corvus Pharmaceuticals, Inc. has a 1-year low of $5.64 and a 1-year high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Sell-side analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

CRVS has been the topic of several analyst reports. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.33.

Insider Transactions at Corvus Pharmaceuticals

In other news, Director David Moore purchased 21,700 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the purchase, the director directly owned 21,700 shares of the company’s stock, valued at approximately $250,201. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 19.70% of the stock is currently owned by insiders.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.